(TEVA) Teva Pharma Industries - Overview
Stock: Generics, Respiratory, CNS, Oncology, API
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 34.5% |
| Relative Tail Risk | -16.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.74 |
| Alpha | 86.85 |
| Character TTM | |
|---|---|
| Beta | 0.920 |
| Beta Downside | 1.079 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.70% |
| CAGR/Max DD | 1.16 |
Description: TEVA Teva Pharma Industries December 17, 2025
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a global developer, manufacturer, and marketer of generic and specialty medicines, operating across the United States, Europe, Israel, and other markets. Its product portfolio spans oral solids, injectables, inhalation devices, transdermal patches, and combination products, with therapeutic focus on central nervous system, respiratory, and oncology indications. In addition to generic APIs and contract-manufacturing services, Teva commercializes branded therapies such as COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and TREANDA (chronic lymphocytic leukemia).
Key recent metrics: 2023 revenue was approximately $13.5 billion, while net debt remained high at roughly $30 billion, reflecting ongoing refinancing pressure. The company’s generic margin has been compressed by intensified price competition and FDA backlog, prompting a strategic shift toward higher-margin specialty and biosimilar launches. Macro-level drivers include an aging global population that sustains demand for CNS and respiratory treatments, and regulatory trends that favor faster biosimilar approvals, which can both create opportunities and heighten competitive risk for Teva.
For a deeper, data-driven valuation, see the TEVA profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 1.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.05 > 1.0 |
| NWC/Revenue: 2.84% < 20% (prev -1.47%; Δ 4.31% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.65b > Net Income 1.41b |
| Net Debt (13.83b) to EBITDA (3.16b): 4.38 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.17b) vs 12m ago 3.53% < -2% |
| Gross Margin: 51.79% > 18% (prev 0.49%; Δ 5130 % > 0.5%) |
| Asset Turnover: 43.11% > 50% (prev 42.07%; Δ 1.04% > 0%) |
| Interest Coverage Ratio: 2.32 > 6 (EBITDA TTM 3.16b / Interest Expense TTM 929.0m) |
Altman Z'' -1.18
| A: 0.01 (Total Current Assets 13.95b - Total Current Liabilities 13.46b) / Total Assets 40.75b |
| B: -0.34 (Retained Earnings -13.76b / Total Assets 40.75b) |
| C: 0.05 (EBIT TTM 2.15b / Avg Total Assets 40.04b) |
| D: -0.49 (Book Value of Equity -16.09b / Total Liabilities 32.84b) |
| Altman-Z'' Score: -1.18 = CCC |
Beneish M -2.93
| DSRI: 1.16 (Receivables 3.71b/3.06b, Revenue 17.26b/16.54b) |
| GMI: 0.94 (GM 51.79% / 48.74%) |
| AQI: 0.99 (AQ_t 0.55 / AQ_t-1 0.56) |
| SGI: 1.04 (Revenue 17.26b / 16.54b) |
| TATA: -0.01 (NI 1.41b - CFO 1.65b) / TA 40.75b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of TEVA shares?
Over the past week, the price has changed by +1.79%, over one month by +8.03%, over three months by +41.82% and over the past year by +100.64%.
Is TEVA a buy, sell or hold?
- StrongBuy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TEVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.8 | 6% |
| Analysts Target Price | 36.8 | 6% |
| ValueRay Target Price | 47.9 | 38.1% |
TEVA Fundamental Data Overview February 07, 2026
P/E Forward = 12.837
P/S = 2.3535
P/B = 5.0819
P/EG = 1.2934
Revenue TTM = 17.26b USD
EBIT TTM = 2.15b USD
EBITDA TTM = 3.16b USD
Long Term Debt = 14.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.82b USD (from shortTermDebt, last quarter)
Debt = 17.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.83b USD (from netDebt column, last quarter)
Enterprise Value = 54.44b USD (40.62b + Debt 17.38b - CCE 3.56b)
Interest Coverage Ratio = 2.32 (Ebit TTM 2.15b / Interest Expense TTM 929.0m)
EV/FCF = 47.42x (Enterprise Value 54.44b / FCF TTM 1.15b)
FCF Yield = 2.11% (FCF TTM 1.15b / Enterprise Value 54.44b)
FCF Margin = 6.65% (FCF TTM 1.15b / Revenue TTM 17.26b)
Net Margin = 8.16% (Net Income TTM 1.41b / Revenue TTM 17.26b)
Gross Margin = 51.79% ((Revenue TTM 17.26b - Cost of Revenue TTM 8.32b) / Revenue TTM)
Gross Margin QoQ = 56.36% (prev 51.43%)
Tobins Q-Ratio = 1.34 (Enterprise Value 54.44b / Total Assets 40.75b)
Interest Expense / Debt = 1.68% (Interest Expense 292.0m / Debt 17.38b)
Taxrate = 21.0% (US default 21%)
NOPAT = 1.70b (EBIT 2.15b * (1 - 21.00%))
Current Ratio = 1.04 (Total Current Assets 13.95b / Total Current Liabilities 13.46b)
Debt / Equity = 2.20 (Debt 17.38b / totalStockholderEquity, last quarter 7.91b)
Debt / EBITDA = 4.38 (Net Debt 13.83b / EBITDA 3.16b)
Debt / FCF = 12.04 (Net Debt 13.83b / FCF TTM 1.15b)
Total Stockholder Equity = 7.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.52% (Net Income 1.41b / Total Assets 40.75b)
RoE = 19.95% (Net Income TTM 1.41b / Total Stockholder Equity 7.06b)
RoCE = 9.76% (EBIT 2.15b / Capital Employed (Equity 7.06b + L.T.Debt 14.99b))
RoIC = 7.10% (NOPAT 1.70b / Invested Capital 23.93b)
WACC = 6.91% (E(40.62b)/V(58.00b) * Re(9.30%) + D(17.38b)/V(58.00b) * Rd(1.68%) * (1-Tc(0.21)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.57%
[DCF Debug] Terminal Value 84.64% ; FCFF base≈1.12b ; Y1≈1.36b ; Y5≈2.20b
Fair Price DCF = 29.42 (EV 47.65b - Net Debt 13.83b = Equity 33.83b / Shares 1.15b; r=6.91% [WACC]; 5y FCF grow 22.07% → 2.90% )
EPS Correlation: 5.23 | EPS CAGR: 16.01% | SUE: 0.80 | # QB: 0
Revenue Correlation: 79.63 | Revenue CAGR: 6.96% | SUE: 1.94 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.55 | Chg30d=-0.034 | Revisions Net=-2 | Analysts=9
EPS current Year (2026-12-31): EPS=2.68 | Chg30d=-0.084 | Revisions Net=-1 | Growth EPS=-8.5% | Growth Revenue=-3.1%
EPS next Year (2027-12-31): EPS=3.09 | Chg30d=-0.043 | Revisions Net=+0 | Growth EPS=+15.1% | Growth Revenue=+2.7%